Navigation Links
InterMune Reports First Quarter 2009 Financial Results and Business Highlights
Date:4/30/2009

terferon gamma-1b) revenue of $6.0 million, compared with $8.5 million in the same quarter of 2008, a decrease of approximately 29%, reflecting lower off-label physician prescriptions of Actimmune for the treatment of IPF, which InterMune does not promote.

Research and development (R&D) expenses in the first quarter of 2009 were $24.4 million compared with $27.2 million in the first quarter of 2008, a decrease of approximately 10%, reflecting completion of the CAPACITY clinical trials in late 2008. General and administrative (G&A) expenses were $8.5 million in the first quarter of 2009, compared with $7.5 million in the same period a year earlier, an increase of approximately 13%, attributed to legal fees associated with a Department of Justice (DOJ) action against a former InterMune executive covered by an indemnification agreement, and costs related to preparation for the anticipated commercialization of pirfenidone.

InterMune additionally reported that first quarter 2009 expenses included a milestone payment of $13.5 million for pirfenidone that was expensed as Acquired Research and Development Milestone. The milestone payment was made in accordance with the pirfenidone purchase agreement and InterMune's decision to submit NDA and MAA filings for pirfenidone.

InterMune also reported expenses of $0.6 million recorded as Restructuring Charges related to a reduction in force in February 2009.

As of March 31, 2009, InterMune had cash, cash equivalents and available-for-sale securities of approximately $175.2 million, compared with $154.7 million at December 31, 2008. The March 31, 2009 balance includes net proceeds of approximately $63.4 million from a follow-on public offering of 4,025,000 shares of common stock completed on February 19, 2009. InterMune made an accelerated payment in the quarter to the DOJ of $4.4 million related to the company's recent financing event. The Ma
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. InterMune to Release First Quarter Financial Results on April 30
2. InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
3. InterMune to Present at Canaccord Adams Hepatitis C Conference
4. InterMune to Present at Citis 4th Annual Biotech Day
5. InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
6. InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
7. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
8. InterMune Announces Issuance of U.S. Patent for ITMN-191
9. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
10. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
11. InterMune to Present at J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014 LayerBio is an MIT spin-off ... care. The National Eye Institute (NEI) at the National ... I SBIR grant to develop a drug-eluting intraocular lens ... common cause of vision loss in people over age ... to Dr. Ken Mandell, LayerBio’s Founder and CEO, "There ...
(Date:12/19/2014)... iLab Solutions, the global leader in core ... as the new Director of Institutional Implementations and Sarah ... two new leadership positions were created to support iLab’s ... iLab continues to meet the needs of its growing ... has been deployed at over 450 core facilities across ...
(Date:12/19/2014)... With only 2 weeks left of 2014, ... Biohit products . The product specials include Buy 1 ... Trade-in Program, and free pipette tips. , Sartorius mLINE ... world. They are ideal for lab technicians performing long ... ,     Full volume range of 0.1 uL to 10 ...
(Date:12/19/2014)... , Dec. 18, 2014   ISN has ... Safety Performance Indicators publication series. With data ... activity reported in 2013 within its online contractor management ... safety key performance indicator (KPI) statistics. ... U.S. publication is available in two industry ...
Breaking Biology Technology:LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2iLab Solutions Announces Two New Leadership Positions to Meet the Needs of Its Growing Customer Base 2Major Pipette Distributor Pipette.com Announces Sartorius Year End Specials 2ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 2ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 3
... have unlocked the physics of the perfect pizza toss ... of micro motors thinner that a human hair. , ... Associate Professor James Friend and Senior Lecturer Leslie Yeo, ... from Monash,s Micro/Nanophysics Research Laboratory, then calculated how best ...
... Encorium Group, Inc. (Nasdaq: ENCO ) ... that provides design, development, and management capabilities for clinical ... leading pharmaceutical companies, today announced the signing of approximately ... new business contracts and repeat business to be conducted ...
... ("Sinobiopharma ", or "the Company") (OTC Bulletin Board: SNBP) ... to seven key patents from Company CEO Dr. Lequn ... significantly enhance Sinobiopharma,s ability to execute on its mission ... are for the following:, , ...
Cached Biology Technology:Pizza tossing art unlocks secrets of tiny motors 2Encorium Group Signs Approximately $2.0 Million of New Business Contracts 2Encorium Group Signs Approximately $2.0 Million of New Business Contracts 3Sinobiopharma Secures Rights to Seven Key Patents 2
(Date:12/17/2014)... DUBLIN , Dec. 16, 2014 Research ... announced the addition of the "Global Chemical ... http://photos.prnewswire.com/prnh/20130307/600769 ... is the increasing demand for medical sensors in ... patient data for quick and correct diagnosis during ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has ... in the APAC Region 2015-2019"  report to their ... in this market is advances in technology. With ... upgrade biometric solutions to the latest standard that ...
(Date:12/11/2014)... PAUL, Minn. , Dec. 10, 2014 /PRNewswire/ ... wireless physiologic monitoring, has released a new series ... needs of preclinical toxicology researchers. M series, part ... help toxicologists collect the best possible physiologic data ... Adding functional endpoints to toxicology studies ...
Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2
... Vision, Inc.,(OTC Bulletin Board: INVI), a leading global ... has received an order for the,Company,s SharpEye(TM) system ... large,computer manufacturer. The SharpEye product provides analysis of ... quality in the manufacturing,process, and the system will ...
... Corporate Safe Specialists (CSS),announces an addition to its ... as National Account Manager., (Photo: http://www.newscom.com/cgi-bin/prnh/20080114/AQM106 ... Currey, Sales Manager of the Company, stated, "the ... accelerate the growth we,ve seen in,networked safe sales. ...
... STATION A specially developed carrot has been produced to ... A&M AgriLifes Vegetable and Fruit Improvement Center studied the calcium ... net increase in calcium absorption. The research, which was done ... carrot to the diet can help prevent such diseases as ...
Cached Biology News:Integral Vision, Inc. Announces SharpEye(TM) Order From New Customer 2Corporate Safe Specialists Announces Addition to Sales Team 2Got carrots? Vegetables may have bone to pick as calcium providers 2